Aqua Pharmaceuticals Announces FDA Approval Of ACTICLATE (Doxycycline Hyclate USP) Tablets, 150 Mg And 75 Mg
7/28/2014 8:52:02 AM
WEST CHESTER, Pa.--(BUSINESS WIRE)--West Chester-based Aqua Pharmaceuticals, an Almirall company, today announces the U.S. Food and Drug Administration (FDA) approval of the NDA for ACTICLATE™ (doxycycline hyclate USP) Tablets, 150 mg and 75 mg, thereby continuing Aqua’s leadership in medical dermatology and oral antibiotics for acne. ACTICLATE™ is a tetracycline-class antibacterial indicated for the treatment of a number of infections, including adjunctive therapy in severe acne.
Help employers find you! Check out all the jobs and post your resume.
comments powered by